ERYTHROVIRUS AND ITS APPLICATIONS

The invention concerns nucleic sequences derived from a human erythrovirus, their fragments and their applications as diagnostic reagent and as immunogenic agent. Said sequences are selected among the sequences having a >/= 10 % genetic divergence over the whole genome with respect to the B19 ery...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	GARBARGNON, ANTOINE, AUGUSTE, VERONIQUE, NGUYEN, QUANG, TRI
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR COMPOSITIONS THEREOF CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES OF PREPARING SUCH COMPOSITIONS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention concerns nucleic sequences derived from a human erythrovirus, their fragments and their applications as diagnostic reagent and as immunogenic agent. Said sequences are selected among the sequences having a >/= 10 % genetic divergence over the whole genome with respect to the B19 erythrovirus sequences, the sequence SEQ ID NO:1 and the nucleotide sequences capable of being hybridized with said sequence ID NO:1. Séquences nucléiques issues d'un érythrovirus humain, leurs fragments ainsi que leurs applications, en tant que réactif de diagnostic et en tant qu'agent immunogène. Ces séquences sont sélectionnées parmi les séquences présentant une divergence génétique >/= 10 % sur l'ensemble du génome par rapport aux séquences de l'érythrovirus B19, la séquence SEQ ID NO:1 et les séquences nucléotidiques capables de s'hybrider avec ladite séquence ID NO:1.